心脉医疗(688016) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached CNY 1,206,473,183.51, a year-on-year increase of 1.6%[3] - Operating profit was CNY 658,339,261.63, reflecting a growth of 14.7% compared to the previous year[3] - Net profit attributable to shareholders was CNY 497,858,188.25, up 1.1% year-on-year[3] - The net profit excluding non-recurring gains and losses decreased by 15.3% to CNY 391,420,967.56[3] - Basic earnings per share fell by 40.7% to CNY 4.04[3] - Total assets at the end of the reporting period amounted to CNY 4,297,194,192.53, a 1.2% increase from the beginning of the year[3] Sales and Market Expansion - Overseas sales revenue exceeded CNY 160 million, growing by over 50% and accounting for more than 13% of total revenue[6] - The company launched multiple new products in the aortic and peripheral business, including balloon occlusion catheters and venous stent systems[8] - The company’s products are now sold in 37 countries and regions, with several achieving first implants in new markets[7] - The company is actively pursuing international market expansion and product registration, including CE and FDA approvals[8]